Please assess the completion status of the following clinical trial:

Trial Title: Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years and less than 80 years.~* Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound.~* Daily requirement of diuretics at least 200mg of spironolactone or 100mg of spironolactone and 40 mg of furosemide~* Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl, blood urea nitrogen ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L.~Exclusion Criteria:~* Refractory Ascites (paracentesis requirements over 1 month.~* Neoplastic disease including liver cancer if it exceeds the Milan criteria (one nodule\> 5 cm or three nodules\> 3 cm).~* History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt~* Gastrointestinal bleeding or bacterial infection documented in the past 15 days.~* Heart failure or structural heart disease.~* Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data nephropathy).~* Moderate or severe lung chronic disease.~* Transplant.~* Infection with human immunodeficiency virus.~* Active addiction to drugs.~* Mental state that prevents the patient understand the nature, extent and consequences of the study, except for hepatic encephalopathy.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (Type: EXPERIMENTAL): The subjects will be receiving albumin 20% infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).